Mansoura Cancer Therapy Center
Al Mansurah, Dakahlia Governorate, 050, Egypt
NCT Number: NCT02562105
This observational cohort aimed to re-evaluate the outcome of hematologic cancer patients admitted to the intensive care unit of Mansoura oncology center through a cohort study as regards their need for mechanical ventilation during two years.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Al Mansurah, Dakahlia Governorate, 050, Egypt
It has been believed for many years that the scene of cancer patients requiring mechanical ventilation is frustrating. The needed life support measures drain much of health resources and add a significant burden on the patient's family. Many factors have been responsible for the high mortality rates among hematologic cancer patients admitted to intensive care unit. Among of these factors, the invasive treatments that are frequently employed in today's intensive care unit. These procedures give chance for development of severe infection and multiple organ failure which are common events in immune-compromised patients (e.g. neutropenia) and in those exposed to chemotherapy. The most common form of organ failure in those patients is acute respiratory failure which is a major predictor of mortality in that population. The prognosis of such failure may vary depending on its causes and severity, co morbidity, associated acute organ failure and characters of the underlying malignancy. After the recent advances in the field of intensive care and shedding light on the benefits of the noninvasive ventilation in immune-compromised patients, the overall survival rate of cancer patients admitted to intensive care unit are improving.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
requiring mechanical ventilation at admission to ICU for one day or more during the study period
Time frame: through study completion, an average of 30 days after admission to intensive care unit
Continuing to live
Time frame: up to 24 hours after admission to the intensive care unit
Sequential Organ Failure Assessment (SOFA) Score
Time frame: up to 24 hours after admission to the intensive care unit
Simplified Acute Physiology Score (SAPS II)
Time frame: up to 24 hours after admission to the intensive care unit
synchronised intermittent, pressure-controlled, volume-controlled, pressure support, continuous positive airway pressure, volume guarantee, adjusted pressure release ventilation, or adaptive proportional assist ventilation
Time frame: up to 24 hours after admission to the intensive care unit
PaO2 "arterial oxygen tension"/FiO2 "inspired fraction of oxygen" ratio
Time frame: up to 24 hours after admission to the intensive care unit
Advanced malignancy, respiratory muscle weakness, respiratory failure, lung metastasis, coma, sepsis, multi-organs failure
Time frame: up to 24 hours after admission to the intensive care unit
Like as sepsis, acute respiratory distress syndorme, or leukopenia
Time frame: up to 24 hours after admission to the intensive care unit
Early or advanced stage
Mansoura University
Other
In a Developing Country; What is the Fate of Hematologic Cancer Patients Requiring Mechanical Ventilation for More Than One Day? A Prospective Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01853358
Hematologic Diseases, Hematologic Neoplasms
Marseille, France
View Trial DetailsNCT03159702
Blood Protein Disorders, Cardiovascular Diseases
Milwaukee, Wisconsin, United States
View Trial DetailsNCT05391022
Advanced Malignancies, Hematologic Diseases
Canton, Ohio, United States
View Trial DetailsNCT03241550
Bacterial Infections and Mycoses, Hematologic Diseases
Long Beach, California, United States
View Trial Details